Biosimilars Have Arrived: Rituximab.
- Published in:
- Arthritis (20901984), 2018, p. 1, doi. 10.1155/2018/3762864
- By:
- Publication type:
- Article
Works by Lea Sewell, K.
Results: 8
1
2
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 11, p. 2182, doi. 10.1111/bcp.14312
- By:
- Publication type:
- Article
3
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
- Published in:
- BioDrugs, 2016, v. 30, n. 6, p. 525, doi. 10.1007/s40259-016-0201-6
- By:
- Publication type:
- Article
4
Patient attitudes and understanding about biosimilars: an international cross-sectional survey.
- Published in:
- Patient Preference & Adherence, 2016, v. 10, p. 937, doi. 10.2147/PPA.S104891
- By:
- Publication type:
- Article
5
Biosimilar biologic drugs: a new frontier in medical care.
- Published in:
- 2017
- By:
- Publication type:
- journal article
6
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
- Published in:
- Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1676-y
- By:
- Publication type:
- Article
7
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
- Published in:
- Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1646-4
- By:
- Publication type:
- Article
8
Phase I Study of FG-3019, an Anti-CTGF Monoclonal Antibody, in Type 1/2 Diabetes Mellitus with Microalbuminuria.
- Published in:
- Diabetes, 2007, v. 56, p. A151
- By:
- Publication type:
- Article